Novel mitochondrial therapies for the treatment of age-related macular degeneration  

作　　者：Aneesha Kalur Justin Muste Carolina C.S.Valentim Amogh Iyer Rishi P.Singh 

机构地区：[1]Center for Ophthalmic Bioinformatics,Cole Eye Institute,Cleveland Clinic,Cleveland,OH,USA [2]Cole Eye Institute-Retina,Cleveland Clinic Foundation,Cleveland,OH,USA

出　　处：《Annals of Eye Science》2021年第4期1-5,共5页眼科学年鉴（英文）

摘　　要：The purpose of this article is to review current literature and data regarding treatment options for age-related macular degeneration(AMD)related to mitochondrial therapy.This article considers the presence of flavoprotein fluorescence as a potential biomarker to test the effectiveness of the treatments.We focus primarily on two major mitochondrial targets,nuclear factor erythroid 2-related factor(NFE2L2)and PGC-1α,that function in controlling the production and effects of reactive oxidative species(ROS)directly in the mitochondria.PU-91 is an FDA approved drug that directly targets and upregulates PGC-1αin AMD cybrid cell lines.Although neither NFE2L2 nor PGC1-αhave yet been tested in clinical trials,their effects have been studied in rodent models and offer promising results.MTP-131,or elamipretide®,and metformin are two drugs in phase II clinical trials that focus on the treatment of advanced,non-exudative AMD.MTP-131 functions by associating with cardiolipin(CL)whereas metformin targets adenosine-monophosphate protein kinase(AMPK)in the mitochondria.The current results of their clinical trials are elucidated in this article.The molecular targets and drugs reviewed in this article show promising results in the treatment of AMD.These targets can be further pursued to improve and refine treatment practices of this diagnosis.

关 键 词：Non-exudative age-related macular degeneration(non-exudative AMD) exudative AMD mitochondrial targets mitochondrial therapy 

分 类 号：R73[医药卫生—肿瘤]